Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$818.93 USD

818.93
5,263,033

-10.81 (-1.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication

Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.

    Mylan (MYL) Launches Generic Version of Lilly's Adcirca

    Mylan (MYL) launches the first generic version of Lilly's Adcirca for the treatment of pulmonary arterial hypertension to improve exercise ability.

      Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings

      Eli Lilly's (LLY) stock is up 15% since announcement of earnings in July. Let us have a look at the reasons for the same.

        Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates

        Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.

          Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y

          Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.

            Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates

            Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.

              AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss

              AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.

                Is Eli Lilly (LLY) a Great Dividend Play?

                Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

                  Radius (RDUS) Q2 Loss Narrower Than Expected, Tymlos Sales Up

                  Radius' (RDUS) Q2 results are encouraging as sales of its lead osteoporosis drug, Tymlos, continue to gain traction.

                    Sweta Killa headshot

                    Q2 Earnings Drive Pharma ETFs Higher

                    The string of strong results pushed pharma ETFs higher, with the four funds posting positive returns over the past one month.

                      United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip

                      United Therapeutics (UTHR) reports unimpressive second-quarter earnings. Sales rise sequentially. Shares sink 5%.

                        Is a Beat in Store for Radius Health (RDUS) in Q2 Earnings?

                        Investors will focus on lead drug Tymlos' uptake and an update on Radius Health's (RDUS) marketing application for the drug in Europe, when it reports second-quarter results on Aug 7.

                          Is Invesco Zacks Multi-Asset Income ETF (CVY) a Hot ETF Right Now?

                          Smart Beta ETF report for CVY

                            Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2

                            Incyte's (INCY) Q2 results were a mixed bag with earnings missing estimates, while revenues beating the same with growth in Jakafi's sales. A milestone payment from Eli Lilly boosted sales as well.

                              Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss

                              Sanofi (SNY) beats earnings but misses on sales in the second quarter of 2018 owing to currency headwinds and struggling diabetes and cardiovascular unit.

                                Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod

                                Earnings are in focus this week with Lilly (LLY), Allergan (AGN) and Glaxo (GSK) delivering strong Q2 numbers. AbbVie (ABBV) gains FDA approval for Elagolix.

                                  Merck (MRK) Q2 Earnings & Sales Top on Keytruda Strength

                                  Merck (MRK) beat estimates for both earnings and sales in second-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.

                                    Incyte (INCY) to Report Q2 Earnings: What's in the Cards?

                                    Incyte (INCY) has a mixed track record. Investors will focus on Jakafi sales and other pipeline updates when the company reports its Q2 results on Jul 31.

                                      Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan

                                      Allergan (AGN) beats second-quarter estimates for earnings and sales and raises its full-year outlook for both the metrics. The board authorizes a new $2.0 billion share buyback plan.

                                        AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up

                                        AstraZeneca (AZN) beats earnings and sales estimates in the second quarter on the back of strong new product sales and maintains previously issued outlook for 2018.

                                          Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up

                                          Glaxo (GSK) beats both earnings and revenues in the second quarter of 2018, and signs a four-year collaboration with 23andMe and invests $300 million for the same.

                                            ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions

                                            The pharma/biotech industry has witnessed a solid start in the Q2 reporting cycle. Let's see if leading players - Merck (MRK) and AbbVie (ABBV) - can contribute further to the encouraging numbers.

                                              AbbVie Secures FDA Approval for Endometriosis Drug Elagolix

                                              AbbVie (ABBV) gains an FDA approval for its late-stage pipeline candidate, Orilissa, for the treatment of moderate to severe pain associated with endometriosis in women.

                                                Company News For Jul 25, 2018

                                                Companies In The News are: HOG,BIIB,LLY,WHR

                                                  Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More

                                                  Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.